In Re Nexium Antitrust Litigation

Welcome to the In re Nexium Antitrust Litigation End-Payor Settlement Website

U.S. District Court for the District of Massachusetts
In re: Nexium (Esomeprazole) Antitrust Litigation
MDL No. 2409

Please be advised that the Court entered the Orders and Judgments Granting Final Approval of Class Action Settlement for both the Dr. Reddy’s and Teva settlements on October 21, 2015. Copies of those Orders can be found by accessing the Court Documents page on this website. Please continue to check this website for further updates.

A lawsuit is pending in the United States District Court for the District of Massachusetts (“the Court”) against four defendants: AstraZeneca, Ranbaxy, Teva, and Dr. Reddy’s (collectively, “Defendants”). “AstraZeneca” includes defendants AstraZeneca AB, Aktiebolaget Hassle, and AstraZeneca LP (collectively, “AstraZeneca”). “Ranbaxy” includes defendants Ranbaxy Pharmaceuticals, Inc., Ranbaxy Inc., and Ranbaxy Laboratories Ltd. (collectively, “Ranbaxy”). “Teva” includes defendants Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”). “Dr. Reddy’s” includes defendants Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “Dr. Reddy’s”).

Plaintiffs in the lawsuit claim that Defendants hurt competition and violated state laws in Arizona, California, Florida, Iowa, Kansas, Massachusetts, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wisconsin, and the District of Columbia by unlawfully delaying the availability of allegedly less expensive generic versions of Nexium. Plaintiffs allege that Defendants’ conduct caused certain consumers and third-party payors (discussed below) to pay too much for Nexium in these states. Defendants deny any wrongdoing.

Settlements have been reached with Dr. Reddy’s and Teva (collectively, “Settling Defendants”). The lawsuit will continue against the other Defendants (collectively, “Non-Settling Defendants”). Copies of court documents are available on the Court Documents tab.

This lawsuit does not claim that Nexium is unsafe or ineffective.
There is no Claim Form to complete, and no monetary distribution to Class Members at this time.